血清CA19-9CLIA法检测的临床应用

目的探讨血清CA19-9化学发光免疫分析(CLIA)检测的临床应用价值。方法回顾分析1243例患者(其中恶性肿瘤511例、非肿瘤疾病732例)与253例健康对照组的血清CA19-9CLIA法检测水平。结果恶性肿瘤中,胰腺癌、胆囊及胆管癌、结直肠癌、胃癌、肝癌、肺癌、乳腺癌等患者血清CA19-9均值及阳性率均显著高于正常对照组(P<0.01);非肿瘤疾病中,胰腺炎、胆囊及胆管疾病、肝硬化等患者血清CA19-9均值及阳性率显著高于正常对照组(P<0.01);胃肠道疾病、肝炎、肺炎、乳腺非肿瘤疾病等患者血清CA19-9均值及阳性率与正常对照组差异均无显著性(P>0.05)。胰腺癌组、胆囊及胆管癌组、结直肠癌组、胃癌组、肺癌组、乳腺癌组CA19-9均值及阳性率分别显著高于其相对应非肿瘤疾病组(P<0.01)。肝癌组均值及阳性率均显著高于肝硬化组及肝炎组(P<0.01),肝硬化组均值及阳性率均显著高于肝炎组(P<0.01)。结论血清CA19-9CLIA法检测可作为速检项目为临床鉴别诊断胰腺癌、胆囊及胆管癌、结直肠癌、胃癌、肝癌、肺癌、乳腺癌等恶性肿瘤及胰腺炎、胆囊及胆管非肿瘤疾病、肝硬化等疾病提供快速可靠的依据。

Clinical Appiication of the Determination of Serum CA19-9 by CLIA

Objective To study the clinical value of the determination of serum CA19-9 by CLIA.Methods The serum CA19-9 levels of 1243 patients(511 malignant tumors and 732 benign lesions)and 253 healthy controls determined by CLIA were reviewed.Results The mean and positive rate of serum CA19-9 in the lpatients of malignant tumors(involving pancreatic cancer,gallbladder and bile duct cancer,colorectal cancer,gastric cancer,liver cancer,lung cancer and breast cancer)and of benign lesions(revolving pancreatic lesions such as pancreatitis,gallbladder and bile duct lesions and hepatocirrhosis)were significantly higher than in healthy controls respectively(P<0.01),but the differences of those between in the pattents of gastrointestinal lesions,hepatitis,lung lesions such as pneumonia and breastlesions and in healthy controls were not significant(P>0.05).Being compared with the relative benign lesion each other,the CA19-9 level and its positive rate in pancreatic cancer,in gallbladder and bile duct cancer,in colorectal cancer,in gastric cancer,in lung cancer and in breast cancer were significantly higher(P<0.01).The CA19-9 level and its positive rate in liver cancer were significantly higher than in hepatocirrhosis and hepatitis respectively(P<0.01),and those in hepatocirrhosis were significantly higher than in hepatitis respectively(P<0.01).Conclusion The determination of serum CA19-9 by CLIA can useas a rapid-determination item to provid a quick and trusty basis for the clinic diagnosis of malignant tumors(mvotving pancreatic cancer,gallbladder and bile duct cancer,colorectal cancer,gastric cancer,liver cancer,lung cancer and breast cancer)and of benign lesions(involving pancreatic lesions such aspancreatitis,gallbladder and bile duct lesions and hepatocirrhosis)as soon as possible.